Abstract
Many postmenopausal women are in the risk of urogenital atrophy development, at present especially because of the generally low use of hormonal replacement therapy. According to the Million Women Study results the number of hormonal replacement therapy 50-64 years-old users in 1996-2000 in Great Britain achieved, from the current point of view, unbelievable 33 percent.
However, current prescription of hormonal replacement therapy presents only a small fraction of this historical record. Urogenital atrophy is expressed by vaginal dyscomfort with dryness, itching and burning of vaginal mucosa, dyspareunia or postcoital bleeding.
Estrogen replacement therapy represents causal way of correction of all estrogen deficiency consequences. Effective and safe local vaginal application of low dose of estrogen is available for postmenopausal women refusing uterine bleeding and some potential risk factors connected with systemic application of estrogens and simultaneously suffering especially from symptoms of urogenital atrophy.